drugset

drugset / Trial / NCT02129751

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

NCT02129751 ↗

Phase 4 Not yet recruiting 246 enrolled Bausch Health Americas, Inc.

RandomizedSingle-groupQuadruple-blindTreatment

Summary

Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety

Timeline

Start: 2026-06
Primary completion: 2029-07
Completion: 2029-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupropion	Small molecule	—	—

Indications